Pancreatic Cancer Market to Hit US$ 11.5 Billion by 2033

Introduction

The global pancreatic cancer market is projected to expand significantly, with an anticipated value of USD 11.5 billion by 2033, rising from USD 3.1 billion in 2023. This growth, expected at a compound annual growth rate (CAGR) of 14.1% from 2024 to 2033, is driven by innovative advancements in treatment protocols and a deeper understanding of the disease’s genetic and cellular underpinnings. A focal point of this advancement is the targeting of the KRAS gene mutation, present in about 90% of pancreatic cancer cases. The shift towards precision medicine, including KRAS-directed and DNA-damage-directed therapies, marks a significant evolution from traditional chemotherapy approaches.

Innovative treatments focus on the cellular microenvironment, crucial for sustaining cancer cell growth under nutrient-deficient conditions. Recent studies have shed light on how pancreatic cancer cells adapt by boosting lysosomal activity. The potential for targeting pathways involved in these adaptations, such as those influenced by proteins like DOCK8—which promotes invasive growth—suggests new avenues for inhibiting cancer progression. This ongoing research underscores the dynamic nature of cancer treatment and the necessity for continuous innovation.

The clinical application of growth factors such as granulocyte colony-stimulating factor (G-CSF) has been reevaluated due to potential adverse effects on survival rates and cancer aggressiveness. Initially used to support immune function during chemotherapy, recent findings suggest that G-CSF may actually hinder patient outcomes by fostering more aggressive cancer traits. This has sparked discussions about refining treatment protocols to manage chemotherapy complications effectively without undermining the immune response to tumors.

Recent developments also highlight significant strides in drug approval and clinical trials, enhancing treatment possibilities. For instance, in December 2022, the FDA approved the use of Pelareorep in combination with Roche’s anti-PD-L1 checkpoint inhibitor atezolizumab, and chemotherapeutic agents gemcitabine and nab-paclitaxel for advanced or metastatic pancreatic ductal adenocarcinoma—a collaborative development by Oncolytics Biotech Inc. Additionally, in March 2023, Novartis announced the phase I clinical development of LGK-974 for metastatic pancreatic cancer, which boasts an 88% phase transition success rate for advancing from phase I to phase II in this specific cancer type.

These developments are integral to the ongoing efforts in refining pancreatic cancer therapies, reflecting a broader industry trend towards more targeted and effective treatment strategies. The continuous research, approval of innovative drugs, and shifting paradigms in treatment approaches collectively fuel the growth of the pancreatic cancer market, emphasizing the critical role of innovation in combating this challenging disease.

Key Takeaways

• Exocrine pancreatic cancer leads the market due to most of the pancreas being made up of exocrine cells.
• Chemotherapy remains the primary treatment for pancreatic cancer in 2023, outpacing other therapies.
• Hospitals are preferred for cancer treatment because they offer comprehensive facilities and a range of therapies.
• Alcohol and cigarette smoking are key drivers of the growing pancreatic cancer market.
• Side effects from chemotherapy and radiation could impede the market’s success.
• In 2023, North America dominates the pancreatic cancer market due to its advanced healthcare system and increasing cancer rates.

Pancreatic Cancer Statistics

2024 :United States

1. In 2024, an estimated 66,440 Americans will be diagnosed with pancreatic cancer.
2. Of these cases, 34,530 will be men and 31,910 will be women.
3. Pancreatic cancer will lead to approximately 51,750 deaths in the U.S., comprising 27,270 men and 24,480 women.
4. The lifetime risk of developing pancreatic cancer is 1 in 56 for men and 1 in 60 for women.
5. Pancreatic cancer is projected to be the third-leading cause of cancer-related death in the U.S.
6. Only 20% of pancreatic cancer cases are surgically resectable at diagnosis.
7. The five-year survival rate for pancreatic cancer has improved to 13% from 6% a decade ago.
8. Smoking accounts for 25% of pancreatic cancer cases.

2024: Global

1. Globally, pancreatic cancer is the seventh leading cause of cancer-related deaths.
2. The overall 5-year survival rate worldwide remains low at 9%.
3. Pancreatic adenocarcinoma accounts for about 90% of all pancreatic cancer cases.
4. Neuroendocrine tumors comprise about 1-2% of pancreatic cancer cases.
5. The highest incidence rates for pancreatic cancer are observed in Northern America and Western Europe.

2023: Australia

1. Australia reported 4,506 new pancreatic cancer cases in 2023, with 2,355 males and 2,151 females.
2. Pancreatic cancer represented 2.7% of all new cancer diagnoses in 2023.
3. There were 3,669 pancreatic cancer deaths in Australia in 2023, including 1,905 males and 1,764 females.
4. Pancreatic cancer accounted for 7.2% of all cancer deaths in Australia in 2023.
5. The five-year survival rate for pancreatic cancer was 13% for cases diagnosed between 2015 and 2019.

2023: Canadian Statistics

1. Canada expected approximately 7,100 new cases of pancreatic cancer in 2023.
2. Of these, 3,800 were estimated to be diagnosed in men and 3,300 in women.
3. Canadian deaths due to pancreatic cancer were anticipated to be about 6,100, with 3,200 men and 2,900 women affected.

2022: United States

1. Around 62,210 Americans were diagnosed with pancreatic cancer in 2022.
2. Approximately 49,830 people died from pancreatic cancer in the U.S. in 2022.
3. Pancreatic cancer diagnoses and deaths each year increased by 0.5% and 0.2%, respectively.
4. The five-year survival rate in the U.S. was reported at 11.5%, an improvement from 3%-5% in the 1990s.

2022 to 2024: Additional Insights and Factors

1. More than 90% of pancreatic cancer cases occur in individuals over the age of 55.
2. Over 70% of patients are aged 70 or older at diagnosis.
3. Genetic factors contribute to 5-10% of pancreatic cancer cases.
4. Obesity increases the risk of pancreatic cancer by 19% for those with a BMI of 30–35 kg/m^2.
5. Long-standing type 2 diabetes doubles the risk of pancreatic cancer.
6. Individuals with hereditary pancreatitis have a 40% lifetime risk of pancreatic cancer.
7. The use of metformin has been associated with a reduced risk of pancreatic cancer in patients with type 2 diabetes.

Emerging Trends

• Targeted Immunotherapies for Pancreatic Cancer: Recent advancements in targeted immunotherapies are showing promise for treating pancreatic cancer. Research has identified that certain pancreatic tumors express neoantigens—unique cancer-specific markers. These can be targeted by immune therapies. Innovations include the development of drugs that inhibit proteins like CD155, which interacts with the TIGIT receptor on T cells. This interaction leads to T cell exhaustion and promotes cancer progression. Emerging treatments combine PD-1 and TIGIT inhibitors with CD40 agonist antibodies. These therapies are demonstrating potential in rejuvenating exhausted T cells and reducing tumor size, offering new hope for effective treatment strategies.
• Novel Chemotherapy Combinations: The FDA has recently approved a groundbreaking first-line chemotherapy regimen named NALIRIFOX for patients with metastatic pancreatic cancer. This treatment combines liposomal irinotecan, 5-FU/leucovorin, and oxaliplatin. It represents a significant advancement, providing improved overall survival rates compared to previous standards of care. This new combination offers renewed hope, particularly for patients facing advanced stages of pancreatic cancer, by providing a more effective treatment option that could potentially extend life expectancy.
• Advancements in Diagnostic Techniques: Enhancements in imaging and diagnostic technologies are revolutionizing the early detection of pancreatic cancer. The integration of artificial intelligence with prediagnostic CT scans has notably improved the capability to identify pancreatic cancer at an earlier stage. Early detection is critical in increasing the effectiveness of treatment options and improving patient outcomes. These technological advancements are key to changing the landscape of pancreatic cancer treatment, potentially leading to higher survival rates.
• Development of a Pancreatic Cancer Vaccine: Innovative efforts in treating pancreatic cancer include the development of a specialized vaccine, currently in clinical trials. This vaccine is designed to train the immune system to recognize and attack pancreatic cancer cells. By focusing on the immune response to the cancer itself, this vaccine aims to treat patients with advanced, even metastatic, stages of the disease. The success of this vaccine could transform the therapeutic approach to pancreatic cancer, offering a new, hopeful avenue for patients battling this aggressive disease.

Use Cases

• Enhanced Surgical Outcomes Through Chemotherapy Advances: Recent advances in chemotherapy have significantly increased the effectiveness of surgery for pancreatic cancer patients. New treatment protocols are effectively shrinking tumors, making them small enough to be surgically removed. This is crucial since surgery offers the best chance of a cure for many patients. The improvements in chemotherapy not only enhance the feasibility of these operations but also boost the overall success rates of these surgical interventions.
• Personalized Treatment Approaches with Genomic Profiling: The application of comprehensive genomic profiling in pancreatic cancer treatment is revolutionizing patient care. This technique involves analyzing the genetic details of a tumor to tailor personalized treatment plans. Oncologists can use this data to prescribe targeted therapies that are more likely to succeed based on the individual genetic makeup of each patient’s cancer. This approach enhances the effectiveness of treatments and optimizes patient outcomes by using precision medicine.
• Exploring Combination Therapy in Clinical Trials: A significant focus in current research is the exploration of combination therapies, especially integrating novel drugs that target specific pathways like TIGIT and PD-1 with established treatments. Clinical trials are essential in this process, as they help determine the most effective treatment combinations. These studies aim to find protocols that not only stop tumor growth but also extend patient survival rates, potentially leading to breakthroughs in how pancreatic cancer is treated.
• Advancements in Gene-Editing for Therapeutic Development: Research into the role of specific proteins, such as DOCK8 which aids the spread of pancreatic cancer cells, is opening new doors for therapeutic strategies. Techniques like CRISPR gene editing are being utilized to disrupt these pathways. By targeting and modifying the genes responsible for aggressive disease progression, researchers are paving the way for treatments that could lead to better disease management and improved prognoses for patients.

Conclusion

In conclusion, the global pancreatic cancer market is poised for substantial growth, driven by advances in treatment protocols and enhanced understanding of the disease’s genetic components. The focus on precision medicine and innovative therapies targeting specific genetic mutations offers new hope for more effective treatment options. Recent regulatory approvals and ongoing clinical trials are instrumental in developing drugs that could revolutionize patient outcomes. Moreover, the shift towards personalized treatment plans and the integration of cutting-edge technologies in diagnostics underline the dynamic evolution of this market. These advancements signal a promising future in the fight against pancreatic cancer, highlighting the importance of continued research and innovation in this field.

Discuss Your Needs With Our Analyst

Please share your requirements with more details so our analyst can check if they can solve your problem(s)

Request a Sample Download PDF